Published • loading... • Updated
CSL Unveils Exclusive Alentis Deal to Advance Rare Disease Treatments
CSL will fund Phase 2 and 3 trials and share global profits 55% to 45% with Alentis.
- On Sunday, CSL and Alentis Therapeutics announced an exclusive global collaboration to co-develop lixudebart, an investigational treatment for rare kidney and liver diseases, in a deal valued at up to $1.6 billion.
- Designed to target claudin-1, lixudebart is an investigational monoclonal antibody that aims to slow inflammation and fibrosis, key drivers of organ damage in kidney and liver diseases.
- Under the partnership, CSL will provide an initial $355 million payment to Alentis and fully fund Phase 2 and Phase 3 trials, with Alentis eligible for up to $1.2 billion in commercial milestone payments.
- Alentis Chief Executive Officer Mark Pruzanski stated the partnership "dramatically accelerates" lixudebart development, while global profits will be shared 55 per cent to CSL and 45 per cent to Alentis once commercialized.
- Beyond initial indications, CSL plans to advance lixudebart for focal segmental glomerulosclerosis and primary sclerosing cholangitis , strengthening its nephrology portfolio with expanded clinical trials.
Insights by Ground AI
15 Articles
15 Articles
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss ...
·London, United Kingdom
Read Full Article
PR Newswire+5 Reposted by 5 other sources
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
/PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote...
·Chicago, United States
Read Full Article
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases - Business News Week
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ — CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become […] The post CSL and Alentis announce global partnership to d…
Coverage Details
Total News Sources15
Leaning Left0Leaning Right2Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
